Recent Considerations in the Application of RAPTA-C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies
Graph Chatbot
Chat with Graph Search
Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.
DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.
This presentation will focus on research carried out in our labs. on organometallic compds. based on the ruthenium(II)-arene unit that exhibit promising in vitro and in vivo anticancer activity and potentially overcome the limitations of platinum based ant ...
Many cancer therapeutic agents elicit resistance that renders them ineffective and often produces cross-resistance to other drugs. One of the most common mechanisms of resistance involves P-glycoprotein (Pgp)-mediated drug efflux. To address this problem, ...
The paper proposes a learning approach to support medical researchers in the context of in-vivo cancer imaging, and specifically in the analysis of Dynamic Contrast-Enhanced MRI (DCE-MRI) data. Tumour heterogeneity is characterized by identifying regions w ...
The present invention relates to a method and a kit for predicting the efficacy of cancer therapy in a subject who has undergone or is undergoing chemotherapy treatment for cancer. ...
A proof-of-principle study on the application of a top-down electrospray ionization Fourier transform ion cyclotron resonance mass spectrometric approach for characterization of the primary binding sites of the platinum anticancer agents cisplatin, transpl ...
Polymers have been extensively utilized in the design of nanometer-sized delivery vehicles of chemotherapeutics for clinical cancer therapy. Polymeric nanoparticulate delivery vehicles, with chemotherapeutics being either conjugated or encapsulated, have b ...
Ruthenium-based anticancer chemotherapies are making significant advances in clinical trials. Until recently, the focus has been on coordination complexes, and mechanisms such as "activation by reduction" and "transferrin-targeted delivery" have been propo ...
The discovery of the anticancer properties of cisplatin in 1965 heralded the development of metallopharmaceuticals and founded a revolution in cancer therapy. Platinum drugs are believed to induce cytotoxicity by cross-linking DNA, causing changes to the D ...
Tumor-infiltrating myeloid cells, including tumor-associated macrophages (TAMs), have been implicated in tumor progression. We recently described a lineage of mouse monocytes characterized by expression of the Tie2 angiopoietin receptor and required for th ...
Doxorubicin has the widest spectrum of antitumor activity of all antineoplastic agents and is the most utilized anticancer drug worldwide. Unfortunately there are several tumor types that do not respond to doxorubicin and, furthermore, its effectiveness is ...
